Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.110
-0.120 (-2.84%)
At close: May 21, 2025, 4:00 PM
4.100
-0.010 (-0.24%)
After-hours: May 21, 2025, 4:00 PM EDT
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 104 employees as of December 31, 2024. The number of employees increased by 4 or 4.00% compared to the previous year.
Employees
104
Change (1Y)
4
Growth (1Y)
4.00%
Revenue / Employee
$852,481
Profits / Employee
-$271,471
Market Cap
186.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
YMAB News
- 8 days ago - Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - GlobeNewsWire
- 8 days ago - Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 14 days ago - Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - GlobeNewsWire
- 15 days ago - Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - GlobeNewsWire
- 24 days ago - Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 26 days ago - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - GlobeNewsWire
- 5 weeks ago - Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity - Seeking Alpha